MA41827A - Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton - Google Patents

Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton

Info

Publication number
MA41827A
MA41827A MA041827A MA41827A MA41827A MA 41827 A MA41827 A MA 41827A MA 041827 A MA041827 A MA 041827A MA 41827 A MA41827 A MA 41827A MA 41827 A MA41827 A MA 41827A
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitor
solvated forms
bruton tyrosine
bruton
Prior art date
Application number
MA041827A
Other languages
English (en)
Inventor
Thierry Bonnaud
Erick Goldman
Garcia Alberto Munoz
Mark Stephen Smyth
Christopher Peter Worrall
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MA41827A publication Critical patent/MA41827A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
MA041827A 2015-03-27 2016-03-24 Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton MA41827A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562139594P 2015-03-27 2015-03-27

Publications (1)

Publication Number Publication Date
MA41827A true MA41827A (fr) 2018-01-30

Family

ID=57006292

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041827A MA41827A (fr) 2015-03-27 2016-03-24 Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton

Country Status (11)

Country Link
US (4) US20180072738A1 (fr)
EP (1) EP3273961A4 (fr)
JP (2) JP2018509457A (fr)
CN (1) CN107530346A (fr)
AU (1) AU2016243116A1 (fr)
BR (1) BR112017020744A2 (fr)
CA (1) CA2981048A1 (fr)
HK (2) HK1248147A1 (fr)
MA (1) MA41827A (fr)
MX (1) MX2017012430A (fr)
WO (1) WO2016160598A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220093389A (ko) 2012-06-04 2022-07-05 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
DK3265084T3 (da) 2015-03-03 2024-02-12 Pharmacyclics Llc Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
WO2017029586A1 (fr) 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Formes cristallines d'ibrutinib
CZ2016276A3 (cs) * 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EP3575300A1 (fr) 2018-05-31 2019-12-04 Apotex Inc. Nouvelles formes cristallines d'ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (fr) 2018-12-21 2020-06-24 Synthon B.V. Composition pharmaceutique comprenant de l'ibrutinib
WO2023242384A1 (fr) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Formes cristallines d'ibrutinib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3303707A1 (de) * 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
KR100274734B1 (ko) 1991-11-22 2000-12-15 제이코버스 코넬리스 레이서 리제드로네이트 지연-방출성 조성물
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
CA2220451A1 (fr) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methodes et compositions pour ameliorer la digestion et l'absorption dans l'intestin grele
CO5210907A1 (es) * 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1664762A4 (fr) 2003-09-03 2008-08-13 Us Gov Health & Human Serv Procedes d'identification, de diagnostic et de prediction pour la survie des lymphomes
SI2530083T1 (sl) 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
ES2562215T3 (es) * 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
US8541391B2 (en) * 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) * 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
KR20220093389A (ko) * 2012-06-04 2022-07-05 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
CN106008515A (zh) * 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法

Also Published As

Publication number Publication date
CA2981048A1 (fr) 2016-10-06
BR112017020744A2 (pt) 2018-07-17
WO2016160598A1 (fr) 2016-10-06
JP2022033783A (ja) 2022-03-02
HK1248147A1 (zh) 2018-10-12
EP3273961A4 (fr) 2018-10-31
EP3273961A1 (fr) 2018-01-31
CN107530346A (zh) 2018-01-02
US20220106317A1 (en) 2022-04-07
MX2017012430A (es) 2018-07-06
US20200347063A1 (en) 2020-11-05
JP2018509457A (ja) 2018-04-05
US20190367519A1 (en) 2019-12-05
HK1249737A1 (zh) 2018-11-09
US20180072738A1 (en) 2018-03-15
AU2016243116A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
ZA201907661B (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
IL255831A (en) Inhibitors of bruton's tyrosine kinase
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
MA41252A (fr) Formes solides d'un inhibiteur d'ask 1
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
MA43162A (fr) Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
EP3414234A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
EP3141546A4 (fr) Inhibiteur de la tyrosine kinase de bruton
MA46180A (fr) Analogues de l'amyline
EP3159340A4 (fr) Nouvel inhibiteur de la tyrosine kinase de bruton
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
MA42510A (fr) Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
MA42509A (fr) Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
MA52629A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
MA49006A (fr) Inhibiteurs d'ip6k
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
MA44607A (fr) Inhibiteurs de kinase